Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL [Yahoo! Finance]
Harrow, Inc. (HROW)
Last harrow, inc. earnings: 11/13 04:21 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
that the Centers for Medicare & Medicaid Services (CMS) has approved Harrow's transitional pass-through application for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is approved by the U.S. Food and Drug Administration (FDA) for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. Beginning April 1, 2025, and for the three years thereafter, TRIESENCE will be eligible for separate reimbursement outside of the surgical bundled payment in both the Ambulatory Surgery Center (ASC) and Hospital Outpatient Department (HOPD) settings of care. CMS previously approved the issuance of
Read more
Impact Snapshot
Event Time:
HROW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HROW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HROW alerts
High impacting Harrow, Inc. news events
Weekly update
A roundup of the hottest topics
HROW
News
- Harrow, Inc. (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $69.00 to $65.00. They now have a "buy" rating on the stock.MarketBeat
- Harrow, Inc. (NASDAQ: HROW) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.MarketBeat
- Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results [Yahoo! Finance]Yahoo! Finance
- Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial ResultsBusiness Wire
- Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025Business Wire
HROW
Earnings
- 11/13/24 - Miss
HROW
Sec Filings
- 3/27/25 - Form 10-K
- 3/27/25 - Form 8-K
- 3/26/25 - Form 4
- HROW's page on the SEC website